{"id":"methyldopate","rwe":[{"pmid":"35833818","year":"2022","title":"Identification of potential biomarkers and small‑molecule compounds related to intracerebral hemorrhage with bioinformatics analysis.","finding":"","journal":"Acta neurobiologiae experimentalis","studyType":"Clinical Study"},{"pmid":"32780460","year":"2021","title":"A novel salvianolic acid A analog with resveratrol structure and its antioxidant activities in vitro and in vivo.","finding":"","journal":"Drug development research","studyType":"Clinical Study"},{"pmid":"7552893","year":"1995","title":"Intravenous antihypertensive agents for patients unable to take oral medications.","finding":"","journal":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","studyType":"Clinical Study"},{"pmid":"1488413","year":"1992","title":"Drug delivery via ion exchange across a micromembrane.","finding":"","journal":"Pharmaceutical research","studyType":"Clinical Study"},{"pmid":"6499654","year":"1984","title":"Spurious increase in serum creatinine associated with intravenous methyldopate therapy.","finding":"","journal":"Drug intelligence & clinical pharmacy","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Adrenergic receptor alpha-2","category":"target"},{"label":"ADRA2A","category":"gene"},{"label":"ADRA2B","category":"gene"},{"label":"ADRA2C","category":"gene"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Merck","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Agonists","category":"pharmacology"},{"label":"Adrenergic alpha-2 Receptor Agonists","category":"pharmacology"},{"label":"Adrenergic alpha-Agonists","category":"pharmacology"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sympatholytics","category":"pharmacology"}],"phase":"marketed","safety":{"contraindications":["Acute hepatitis","Anemia","Angina pectoris","Autoimmune hemolytic anemia","Chronic heart failure","Cirrhosis of liver","Depressive disorder","Disease of liver","Edema","Hepatic failure","Kidney disease","Parkinsonism","Pheochromocytoma","Porphyria","Severe Cerebrovascular Disease"]},"trials":[],"aliases":[],"company":"Merck & Co.","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=METHYLDOPATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:07:41.780616+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:07:47.274279+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=METHYLDOPATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:07:47.681144+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Adrenergic receptor alpha-2 agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:07:48.727276+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200432/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:07:48.381391+00:00"}},"allNames":"aldomet","offLabel":[],"synonyms":["methyldopate","methyldopate hydrochloride","Methyl-L-dopa ethyl ester","alpha-Methyldopa ethyl ester","methyldopate HCl"],"timeline":[{"date":"1962-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from MERCK to Merck"},{"date":"1962-12-20","type":"positive","source":"DrugCentral","milestone":"FDA approval (Merck)"},{"date":"1987-12-22","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 6 manufacturers approved"}],"approvals":[{"date":"1962-12-20","orphan":false,"company":"MERCK","regulator":"FDA"}],"brandName":"Aldomet","ecosystem":[{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null}],"mechanism":{"target":"Adrenergic receptor alpha-2","novelty":"Follow-on","targets":[{"gene":"ADRA2A","source":"DrugCentral","target":"Adrenergic receptor alpha-2","protein":"Alpha-2A adrenergic receptor"},{"gene":"ADRA2B","source":"DrugCentral","target":"Adrenergic receptor alpha-2","protein":"Alpha-2B adrenergic receptor"},{"gene":"ADRA2C","source":"DrugCentral","target":"Adrenergic receptor alpha-2","protein":"Alpha-2C adrenergic receptor"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Aldomet exerts its effects by activating the alpha-2 adrenergic receptors in the central nervous system, which leads to a decrease in sympathetic tone and a subsequent reduction in blood pressure."},"commercial":{"launchDate":"1962","_launchSource":"DrugCentral (FDA 1962-12-20, MERCK)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4218","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=METHYLDOPATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=METHYLDOPATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:39:29.906300","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:07:50.004942+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"corbadrine","drugSlug":"corbadrine","fdaApproval":"1960-01-06","relationship":"same-target"},{"drugName":"medetomidine","drugSlug":"medetomidine","fdaApproval":"","relationship":"same-target"},{"drugName":"phenylephrine","drugSlug":"phenylephrine","fdaApproval":"1952-01-21","patentExpiry":"Sep 26, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"vilazodone","drugSlug":"vilazodone","fdaApproval":"2011-01-21","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"methyldopate","indications":{"approved":[{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Merck","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"corbadrine","brandName":"corbadrine","genericName":"corbadrine","approvalYear":"1960","relationship":"same-target"},{"drugId":"medetomidine","brandName":"medetomidine","genericName":"medetomidine","approvalYear":"","relationship":"same-target"},{"drugId":"phenylephrine","brandName":"phenylephrine","genericName":"phenylephrine","approvalYear":"1952","relationship":"same-target"},{"drugId":"vilazodone","brandName":"vilazodone","genericName":"vilazodone","approvalYear":"2011","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT04246437","phase":"PHASE1","title":"[18F]F-DOPA Imaging in Patients With Autonomic Failure","status":"RECRUITING","sponsor":"Daniel Claassen","startDate":"2020-02-04","conditions":["Autonomic Failure","Pure Autonomic Failure","Parkinson Disease","Multiple System Atrophy","Dementia With Lewy Bodies"],"enrollment":40,"completionDate":"2027-02-01"},{"nctId":"NCT07151378","phase":"PHASE3","title":"Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-10-27","conditions":["PARKINSON DISEASE (Disorder)"],"enrollment":150,"completionDate":"2030-09-22"},{"nctId":"NCT07442591","phase":"PHASE1","title":"A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"Shanghai WD Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":["Healhty"],"enrollment":12,"completionDate":"2026-12"},{"nctId":"NCT04469959","phase":"PHASE2","title":"Dopaminergic Dysfunction in Late-Life Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-02-15","conditions":["Late Life Depression","Cognitive Decline","Depressive Disorder, Treatment-Resistant","Levodopa","Gait Impairment"],"enrollment":100,"completionDate":"2026-07-30"},{"nctId":"NCT07349277","phase":"","title":"Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia","status":"RECRUITING","sponsor":"Ammar Jassim Abed","startDate":"2025-10-10","conditions":["Preeclampsia","Gestational Hypertension","Hypertensive Disorders of Pregnancy"],"enrollment":120,"completionDate":"2026-04-30"},{"nctId":"NCT06618521","phase":"NA","title":"Effect of Pilates Exercise Versus Circuit Exercise Training on Gestational Hypertension","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-09-30","conditions":["Gestational Hypertension"],"enrollment":69,"completionDate":"2025-10-31"},{"nctId":"NCT06587217","phase":"PHASE1,PHASE2","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2024-10-29","conditions":["Parkinsonian Signs in Older Persons"],"enrollment":5,"completionDate":"2025-04-03"},{"nctId":"NCT04520178","phase":"PHASE2,PHASE3","title":"Effects of 5HTP on the Injured Human Spinal Cord","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2020-07-01","conditions":["Spinal Cord Injuries"],"enrollment":30,"completionDate":"2026-12-30"},{"nctId":"NCT04821830","phase":"PHASE4","title":"Vigor and the LDR in Parkinson Disease","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2020-02-12","conditions":["Parkinson Disease"],"enrollment":19,"completionDate":"2024-04-25"},{"nctId":"NCT07044232","phase":"PHASE4","title":"NICardipine for Fast Achievement of Systolic BP Targets in ICH","status":"NOT_YET_RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-10-01","conditions":["Intracerebral Haemorrhage"],"enrollment":88,"completionDate":"2027-12-31"},{"nctId":"NCT06219915","phase":"PHASE1,PHASE2","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2024-03-15","conditions":["Parkinsonian Signs in Older Persons"],"enrollment":13,"completionDate":"2024-05-30"},{"nctId":"NCT03735901","phase":"PHASE3","title":"Enhancement of Stroke Rehabilitation With Levodopa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2019-06-14","conditions":["Acute Stroke","Stroke Rehabilitation"],"enrollment":610,"completionDate":"2029-06-30"},{"nctId":"NCT04325503","phase":"PHASE1,PHASE2","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2021-02-08","conditions":["Parkinsonian Signs in Older Persons"],"enrollment":14,"completionDate":"2022-06-30"},{"nctId":"NCT06161220","phase":"PHASE1","title":"A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2023-10-30","conditions":["Cardiac Repolarization in Healthy Subjects"],"enrollment":35,"completionDate":"2023-12-05"},{"nctId":"NCT01323374","phase":"PHASE2","title":"Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia","status":"COMPLETED","sponsor":"Chelsea Therapeutics","startDate":"2009-01","conditions":["Fibromyalgia"],"enrollment":122,"completionDate":"2011-10"},{"nctId":"NCT01883505","phase":"PHASE2","title":"A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2014-01-06","conditions":["Parkinson's Disease"],"enrollment":30,"completionDate":"2015-04-26"},{"nctId":"NCT04835233","phase":"PHASE4","title":"Management of Hypertension in the Early Postpartum: a Randomized Controlled Trial","status":"COMPLETED","sponsor":"Federal University of Paraíba","startDate":"2021-05-01","conditions":["Pregnancy-Induced Hypertension in Postpartum","Postpartum Pre-Eclampsia","Hypertension"],"enrollment":180,"completionDate":"2022-12-31"},{"nctId":"NCT06180720","phase":"PHASE1","title":"Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in the Postprandial State in Healthy Chinese Subjects","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2023-12-20","conditions":["Healthy"],"enrollment":36,"completionDate":"2024-11-20"},{"nctId":"NCT05888896","phase":"NA","title":"Effect of Foot Reflexology on Preeclampsia","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-06-09","conditions":["Mild Pre-eclampsia"],"enrollment":60,"completionDate":"2023-09-20"},{"nctId":"NCT01770145","phase":"PHASE4","title":"Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)","status":"COMPLETED","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2012-12","conditions":["Parkinson's Disease","Motor Symptoms","Akinesia","Hypomobility","Delayed Levodopa Onset"],"enrollment":127,"completionDate":"2014-04"},{"nctId":"NCT05976737","phase":"PHASE1","title":"Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in Healthy Chinese Subjects","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2023-08-17","conditions":["Healthy"],"enrollment":68,"completionDate":"2024-07-12"},{"nctId":"NCT03761030","phase":"PHASE4","title":"L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2019-01-09","conditions":["Major Depressive Disorder","Dysthymia","Depression"],"enrollment":51,"completionDate":"2021-09-08"},{"nctId":"NCT04952194","phase":"PHASE4","title":"Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-01-01","conditions":["Parkinson Disease"],"enrollment":180,"completionDate":"2023-12-31"},{"nctId":"NCT04380142","phase":"PHASE3","title":"Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-10-19","conditions":["Parkinson's Disease (PD)"],"enrollment":174,"completionDate":"2021-09-29"},{"nctId":"NCT04000919","phase":"PHASE2,PHASE3","title":"Effects of 5HTP and LDOPA on CNS Excitability After SCI","status":"SUSPENDED","sponsor":"Jessica M D'Amico","startDate":"2019-06-19","conditions":["Spinal Cord Injuries"],"enrollment":30,"completionDate":"2023-12-30"},{"nctId":"NCT03205956","phase":"PHASE1","title":"Measuring Parkinson's Disease Progression","status":"COMPLETED","sponsor":"Kevin J. Black, MD","startDate":"2017-10-19","conditions":["Parkinson's Disease"],"enrollment":31,"completionDate":"2019-10-19"},{"nctId":"NCT05211609","phase":"NA","title":"Prevalence of High Plasmatic 3OMethyldopa Level in a Specific Population of Patients With a Symptomatology Compatible With AADC Deficiency","status":"UNKNOWN","sponsor":"University Hospital, Montpellier","startDate":"2022-05-20","conditions":["Aromatic L-Amino Acid Decarboxylase Deficiency"],"enrollment":388,"completionDate":"2024-11-01"},{"nctId":"NCT04778176","phase":"PHASE2","title":"Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"SynAgile Corporation","startDate":"2021-06-16","conditions":["Parkinson's Disease"],"enrollment":17,"completionDate":"2022-08-02"},{"nctId":"NCT05250141","phase":"PHASE1","title":"Bioavailability of Levodopa 250 mg and Carbidopa 25 mg With Regards to Reference Product","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2022-02-14","conditions":["Bioequivalence"],"enrollment":44,"completionDate":"2022-02-17"},{"nctId":"NCT02553265","phase":"PHASE2","title":"Carbidopa for the Treatment of Excessive Blood Pressure Variability","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2015-09","conditions":["Dysautonomia, Familial","Baroreflex Failure Syndrome"],"enrollment":22,"completionDate":"2019-05-10"},{"nctId":"NCT00685919","phase":"PHASE2,PHASE3","title":"Peripheral Dopamine in Postural Tachycardia Syndrome","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2008-05","conditions":["Postural Tachycardia Syndrome","Orthostatic Intolerance"],"enrollment":32,"completionDate":"2021-12"},{"nctId":"NCT01883804","phase":"NA","title":"Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-06","conditions":["Diabetes Mellitus, Type 1"],"enrollment":30,"completionDate":"2016-02"},{"nctId":"NCT04625595","phase":"PHASE1","title":"Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes","status":"COMPLETED","sponsor":"Immunomolecular Therapeutics, Inc.","startDate":"2020-11-09","conditions":["Type1 Diabetes"],"enrollment":30,"completionDate":"2021-07-31"},{"nctId":"NCT04764383","phase":"PHASE2","title":"Histaminergic Basis of Fatigue in Multiple Sclerosis","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2022-01-01","conditions":["Multiple Sclerosis"],"enrollment":0,"completionDate":"2022-10-30"},{"nctId":"NCT03055936","phase":"PHASE1","title":"Dose-finding Pharmacokinetic Study in Healthy Males","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2017-02-21","conditions":["Healthy Volunteers"],"enrollment":56,"completionDate":"2017-06-09"},{"nctId":"NCT00748059","phase":"PHASE1","title":"The Pathophysiology of Orthostatic Hypotension","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"1996-12","conditions":["Autonomic Nervous System Diseases","Orthostatic Hypotension","Dopamine Beta-Hydroxylase Deficiency","Orthostatic Intolerance"],"enrollment":10,"completionDate":"2020-12"},{"nctId":"NCT00914602","phase":"PHASE1,PHASE2","title":"An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2009-05","conditions":["Parkinson's Disease"],"enrollment":14,"completionDate":"2010-01"},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":["Hypertension","COVID"],"enrollment":22213,"completionDate":"2020-12-31"},{"nctId":"NCT02531490","phase":"PHASE4","title":"Early Vascular Adjustments During Hypertensive Pregnancy","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2015-01-01","conditions":["Hypertension, Pregnancy-Induced","Pre-Eclampsia"],"enrollment":368,"completionDate":"2023-04"},{"nctId":"NCT01683253","phase":"PHASE4","title":"Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa","status":"COMPLETED","sponsor":"Sandoz","startDate":"2012-11","conditions":["Impulse Control Disorder"],"enrollment":150,"completionDate":"2014-12"},{"nctId":"NCT01171313","phase":"PHASE2","title":"A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2010-07","conditions":["Parkinson's Disease"],"enrollment":35,"completionDate":"2011-12"},{"nctId":"NCT03266965","phase":"PHASE1","title":"Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach","status":"COMPLETED","sponsor":"University of Miami","startDate":"2018-03-23","conditions":["Multiple Sclerosis"],"enrollment":18,"completionDate":"2020-08-07"},{"nctId":"NCT02799381","phase":"PHASE3","title":"A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-02-09","conditions":["Parkinson's Disease (PD)"],"enrollment":63,"completionDate":"2019-09-19"},{"nctId":"NCT03541356","phase":"PHASE2","title":"Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal","status":"COMPLETED","sponsor":"Impel Pharmaceuticals","startDate":"2018-05-08","conditions":["Parkinson's Disease"],"enrollment":32,"completionDate":"2019-06-11"},{"nctId":"NCT03396484","phase":"PHASE2","title":"Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes","status":"WITHDRAWN","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2020-09","conditions":["Type1 Diabetes Mellitus"],"enrollment":0,"completionDate":"2022-03"},{"nctId":"NCT04216706","phase":"","title":"Early Vascular Adjustments to Prevent Preeclampsia","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2014-11-01","conditions":["Preeclampsia","Small for Gestational Age at Delivery","HELLP Syndrome"],"enrollment":314,"completionDate":"2020-03-01"},{"nctId":"NCT03115827","phase":"PHASE4","title":"Norepinephrine-targeted Therapy for Action Control in Parkinson Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2017-04-18","conditions":["Parkinson Disease"],"enrollment":15,"completionDate":"2018-12-21"},{"nctId":"NCT04082715","phase":"PHASE2","title":"Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity","status":"WITHDRAWN","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2019-10","conditions":["Chronic Back Pain"],"enrollment":0,"completionDate":"2023-12"},{"nctId":"NCT01399905","phase":"PHASE2","title":"High and Low Dose Carbidopa Treatment of Parkinson's Disease","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2009-03","conditions":["Parkinson's Disease"],"enrollment":14,"completionDate":"2011-05"},{"nctId":"NCT01911494","phase":"NA","title":"Community Level Interventions for Pre-eclampsia","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2013-09","conditions":["Pre-eclampsia","Hypertension, Pregnancy Induced"],"enrollment":87500,"completionDate":"2018-06"},{"nctId":"NCT01912677","phase":"PHASE4","title":"Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy","status":"COMPLETED","sponsor":"Gynuity Health Projects","startDate":"2015-04","conditions":["Hypertension in Pregnancy","Preeclampsia"],"enrollment":894,"completionDate":"2017-12"},{"nctId":"NCT00845000","phase":"PHASE1","title":"Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-21","conditions":["Parkinson Disease"],"enrollment":12,"completionDate":"2010-05-14"},{"nctId":"NCT03576638","phase":"PHASE2","title":"Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients","status":"UNKNOWN","sponsor":"Intec Pharma Ltd.","startDate":"2018-07","conditions":["Parkinson Disease"],"enrollment":12,"completionDate":"2019-01"},{"nctId":"NCT01437293","phase":"PHASE1","title":"Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE)","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2010-08","conditions":["Cocaine Abuse"],"enrollment":15,"completionDate":"2012-04"},{"nctId":"NCT00329511","phase":"NA","title":"A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy","status":"WITHDRAWN","sponsor":"Afshan B. Hameed, M.D.","startDate":"2004-09","conditions":["Hypertension"],"enrollment":0,"completionDate":"2008-12"},{"nctId":"NCT03210025","phase":"PHASE1","title":"Clinical Bioequivalence Study on Two Methyldopa Tablet 250mg Formulations","status":"COMPLETED","sponsor":"Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited","startDate":"2017-09-20","conditions":["Healthy"],"enrollment":17,"completionDate":"2017-10-15"},{"nctId":"NCT00223717","phase":"PHASE1","title":"Treatment of Supine Hypertension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2001-01","conditions":["Hypertension"],"enrollment":152,"completionDate":"2017-01"},{"nctId":"NCT03140956","phase":"PHASE1","title":"Pharmacokinetic of Levodopa Study in Healthy Males","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2017-04-19","conditions":["Parkinson Disease"],"enrollment":20,"completionDate":"2017-08-03"},{"nctId":"NCT01617135","phase":"PHASE2","title":"Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and \"Off\" Episodes","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2012-05","conditions":["Idiopathic Parkinson's Disease"],"enrollment":25,"completionDate":"2012-12"},{"nctId":"NCT00194974","phase":"PHASE1,PHASE2","title":"Treatment Targets for Chronic Hypertension in Pregnancy","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2004-07","conditions":["Pregnancy Toxemia","Hypertension","Proteinuria"],"enrollment":0,"completionDate":"2005-03"},{"nctId":"NCT00580619","phase":"PHASE1","title":"Autonomic Nervous System and Chronic Fatigue Syndrome","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2007-04","conditions":["Chronic Fatigue Syndrome","Orthostatic Intolerance","Postural Tachycardia Syndrome"],"enrollment":170,"completionDate":"2017-01"},{"nctId":"NCT00223691","phase":"PHASE1","title":"Treatment of Orthostatic Hypotension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2002-03","conditions":["Autonomic Failure","Orthostatic Hypotension"],"enrollment":389,"completionDate":"2017-01"},{"nctId":"NCT00829439","phase":"PHASE1","title":"Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2009-01","conditions":["Angelman Syndrome"],"enrollment":16,"completionDate":"2010-06"},{"nctId":"NCT01500590","phase":"PHASE4","title":"Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria","status":"UNKNOWN","sponsor":"Hospital Authority, Hong Kong","startDate":"2011-11","conditions":["Diabetes","Hypertensive Disease"],"enrollment":1400,"completionDate":"2019-08"},{"nctId":"NCT00141518","phase":"PHASE4","title":"Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2006-03","conditions":["Advanced Idiopathic Parkinson's Disease"],"enrollment":77,"completionDate":"2011-04"},{"nctId":"NCT02633839","phase":"PHASE1","title":"A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2015-12","conditions":["Smoking"],"enrollment":60,"completionDate":"2016-06"},{"nctId":"NCT02633007","phase":"PHASE1","title":"A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2015-12","conditions":["Asthma"],"enrollment":25,"completionDate":"2016-05"},{"nctId":"NCT01479127","phase":"PHASE2","title":"Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-10","conditions":["Advanced Parkinson's Disease"],"enrollment":8,"completionDate":"2012-07"},{"nctId":"NCT01212484","phase":"PHASE3","title":"Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2009-12","conditions":["Familial Dysautonomia"],"enrollment":12,"completionDate":"2012-10"},{"nctId":"NCT01636037","phase":"PHASE2","title":"Antipsychotic Augmentation With L-Dopa","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2012-09","conditions":["Schizophrenia"],"enrollment":13,"completionDate":"2016-01"},{"nctId":"NCT02554734","phase":"PHASE1","title":"Pharmacokinetic Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2015-08","conditions":["Parkinson's Disease"],"enrollment":15,"completionDate":"2015-11"},{"nctId":"NCT00218075","phase":"PHASE2","title":"Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2000-03","conditions":["Cocaine Abuse","Cocaine-Related Disorders"],"enrollment":200,"completionDate":"2007-10"},{"nctId":"NCT01533077","phase":"PHASE1","title":"Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2009-03","conditions":["Parkinson Disease"],"enrollment":18,"completionDate":"2010-02"},{"nctId":"NCT01470859","phase":"NA","title":"The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2011-12","conditions":["Idiopathic Parkinson's Disease"],"enrollment":30,"completionDate":"2014-08"},{"nctId":"NCT01227655","phase":"PHASE3","title":"Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2011-03","conditions":["Parkinson's Disease"],"enrollment":427,"completionDate":"2012-07"},{"nctId":"NCT01568073","phase":"PHASE3","title":"Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With \"Wearing-off\" Phenomenon","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2011-03","conditions":["Parkinson's Disease"],"enrollment":600,"completionDate":"2013-11"},{"nctId":"NCT02486432","phase":"PHASE1","title":"A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2015-04","conditions":["Parkinson's Disease"],"enrollment":6,"completionDate":"2015-04"},{"nctId":"NCT02312232","phase":"PHASE1","title":"Pharmacokinetic Study in Healthy Males","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2014-11","conditions":["Parkinson's Disease"],"enrollment":20,"completionDate":"2015-02"},{"nctId":"NCT00547911","phase":"PHASE1,PHASE2","title":"Augmenting Effects of L-DOPS With Carbidopa and Entacapone","status":"TERMINATED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2007-10","conditions":["Parkinson Disease","Multiple System Atrophy","Autonomic Nervous System Diseases"],"enrollment":14,"completionDate":"2013-04"},{"nctId":"NCT01766258","phase":"PHASE2","title":"Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2011-05","conditions":["Parkinson's Disease"],"enrollment":117,"completionDate":"2012-09"},{"nctId":"NCT01218425","phase":"NA","title":"Dopaminergic Modulation of Cognition and Psychomotor Function","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2010-11","conditions":["Dopamine Activity","Episodic Memory Consolidation","Response Preparation"],"enrollment":20,"completionDate":"2012-06"},{"nctId":"NCT01674127","phase":"PHASE2","title":"Effect of Methyldopa on Uterine Artery Diameter in Pregnant Women With Mild Preeclampsia","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","startDate":"2011-08","conditions":["Pregnant Women With Mild Preeclampsia"],"enrollment":50,"completionDate":"2012-05"},{"nctId":"NCT01229332","phase":"PHASE1,PHASE2","title":"A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2011-01","conditions":["Parkinson's Disease"],"enrollment":24,"completionDate":"2011-11"},{"nctId":"NCT01296464","phase":"PHASE2","title":"Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2011-02","conditions":["Parkinson's Disease"],"enrollment":27,"completionDate":"2011-07"},{"nctId":"NCT01361425","phase":"PHASE4","title":"Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)","status":"UNKNOWN","sponsor":"Professor Fernando Figueira Integral Medicine Institute","startDate":"2011-05","conditions":["Preeclampsia"],"enrollment":200,"completionDate":"2013-02"},{"nctId":"NCT01070628","phase":"PHASE1","title":"Levodopa Concentration Profile With Stalevo 75/125 mg","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2009-12","conditions":["Parkinson's Disease"],"enrollment":20,"completionDate":"2010-02"},{"nctId":"NCT00117546","phase":"PHASE4","title":"Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2005-09","conditions":["Preeclampsia"],"enrollment":35,"completionDate":"2008-12"},{"nctId":"NCT00460954","phase":"","title":"A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-06","conditions":["Parkinson's Disease"],"enrollment":20,"completionDate":"2007-08"},{"nctId":"NCT00562198","phase":"PHASE2","title":"PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding","status":"TERMINATED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2008-01","conditions":["Parkinson´s Disease"],"enrollment":16,"completionDate":"2008-05"},{"nctId":"NCT00693862","phase":"PHASE1","title":"Pharmacokinetic Study With Repeated Doses of Stalevo","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2006-12","conditions":["Pharmacokinetics"],"enrollment":19,"completionDate":"2008-05"},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":["Hypertension"],"enrollment":52,"completionDate":"2005-09"},{"nctId":"NCT00174239","phase":"PHASE4","title":"Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2004-07","conditions":["Parkinson Disease"],"enrollment":220,"completionDate":"2005-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000020157","MMSL":"5089","NDDF":"000647","UNII":"2579Z4P04J","VUID":"4022151","CHEBI":"CHEBI:94761","VANDF":"4017963","RXNORM":"6877","UMLSCUI":"C0025744","chemblId":"CHEMBL1200432","ChEMBL_ID":"CHEMBL1201233","KEGG_DRUG":"D04997","PUBCHEM_CID":"17277","SNOMEDCT_US":"21566004","SECONDARY_CAS_RN":"2508-79-4","MESH_DESCRIPTOR_UI":"D008750"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1962-","companyName":"Merck","relationship":"Original Developer"}],"publicationCount":14,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"originalDeveloper":"Merck","recentPublications":[{"date":"2022","pmid":"35833818","title":"Identification of potential biomarkers and small‑molecule compounds related to intracerebral hemorrhage with bioinformatics analysis.","journal":"Acta neurobiologiae experimentalis"},{"date":"2021 Feb","pmid":"32780460","title":"A novel salvianolic acid A analog with resveratrol structure and its antioxidant activities in vitro and in vivo.","journal":"Drug development research"},{"date":"1995 Jul 15","pmid":"7552893","title":"Intravenous antihypertensive agents for patients unable to take oral medications.","journal":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists"},{"date":"1992 Dec","pmid":"1488413","title":"Drug delivery via ion exchange across a micromembrane.","journal":"Pharmaceutical research"},{"date":"1984 Nov","pmid":"6499654","title":"Spurious increase in serum creatinine associated with intravenous methyldopate therapy.","journal":"Drug intelligence & clinical pharmacy"}],"companionDiagnostics":[],"genericManufacturers":7,"_genericFilersChecked":true,"genericManufacturerList":["Abraxis Pharm","Am Regent","Baxter Hlthcare","Hospira","Marsam Pharms Llc","Smith And Nephew","Teva Parenteral"],"status":"approved","companyName":"Merck","companyId":"merck","modality":"Small molecule","firstApprovalDate":"1962","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1962-12-20T00:00:00.000Z","mah":"MERCK","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:07:50.004942+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}